ReviewDrug design, development and therapy2025
Curculigoside is a Promising Osteoprotective Agent for Osteoporosis: Review.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in research on the relationship between mitochondrial dysfunction and osteoporosis: a bibliometric study from 2014 to 2024.Frontiers in medicine · 2025Pooled it
- Mitigating mitochondrial dysfunction: a novel strategy for Chinese botanical drugs against osteoporosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevention and treatment of osteoporosis (OP) is one of the major issues in coping with the aging population; however, there are limited treatments available for OP. In-depth study of OP pathogenesis and development of new therapeutic strategies has become an urgent medical need facing the aging society. Curculigoside is a natural product widely found in plants, which can modulate cellular differentiation and function in osteogenic cells and exert significant osteoprotective effects. In addition, curculigoside showed significant positive effects on the treatment of OP animal models. Specific mechanisms include inhibition of inflammatory responses, antagonism of oxidative stress, and modulation of various signaling. Therefore, we hypothesized that curculigoside could represent a novel therapeutic strategy for OP. This article reviews recent research advances in the treatment of OP with curculigoside, including the origin and basic characteristics of curculigoside, the mechanisms and therapeutic effects that may be involved in in vitro as well as in vivo studies. We also examine the pharmacokinetics of curculigoside and investigate modified uses that may augment its therapeutic efficacy. This article seeks to encourage additional investigation into curculigoside-based treatments for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.